Comparative chemical array screening for p38γ/δ MAPK inhibitors using a single gatekeeper residue difference between p38α/β and p38γ/δ

被引:0
|
作者
Yasumitsu Kondoh
Kaori Honda
Sayoko Hiranuma
Teruo Hayashi
Takeshi Shimizu
Nobumoto Watanabe
Hiroyuki Osada
机构
[1] Antibiotics Laboratory,
[2] RIKEN,undefined
[3] Chemical Biology Research Group,undefined
[4] RIKEN Center for Sustainable Resource Science,undefined
[5] Bio-Active Compounds Discovery Research Unit,undefined
[6] RIKEN Center for Sustainable Resource Science,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Mammalian p38 mitogen activated protein kinases (MAPKs) are responsive to a variety of cellular stresses. The development of specific pyridinyl imidazole inhibitors has permitted the characterization of the p38 MAPK isoform p38α, which is expressed in most cell types, whereas the physiological roles of p38γ and p38δ are poorly understood. In this study, we report an approach for identifying selective inhibitors against p38γ and p38δ by focusing on the difference in gatekeeper residues between p38α/β and p38γ/δ. Using GST-fused p38α wild type and T106M mutant constructs, wherein the p38α gatekeeper residue (Thr-106) was substituted by the p38γ/δ-type (Met), we performed comparative chemical array screening to identify specific binders of the mutant and identified SU-002 bound to p38αT106M specifically. SU-002 was found to inhibit p38αT106M but not p38α kinase activity in in vitro kinase assays. SU-005, the analog of SU-002, had inhibitory effects against the kinase activity of p38γ and p38δ in vitro but not p38α. In addition, SU-005 inhibited both p38γ and p38δ auto-phosphorylation in HeLa and HEK293T cells. These results demonstrate that the comparative chemical array screening approach is a powerful technique to explore specific inhibitors for mutant proteins with even single amino-acid substitutions in a high-throughput manner.
引用
收藏
相关论文
共 50 条
  • [41] The as-yet unfulfilled promise of p38 MAPK inhibitors
    Sweeney, Susan E.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (09) : 475 - 477
  • [42] NSAIDs inhibit p38 MAPK activation
    Cheryl Smythe
    [J]. Arthritis Research & Therapy, 4 (1)
  • [43] Activin can activate p38 MAPK
    Neumann E.
    [J]. Breast Cancer Research, 3 (1)
  • [44] Inhibition of Neuronal p38α, but not p38β MAPK, Provides Neuroprotection Against Three Different Neurotoxic Insults
    Xing, Bin
    Bachstetter, Adam D.
    Van Eldik, Linda J.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2015, 55 (02) : 509 - 518
  • [45] Increased activation of p38 MAPK in COPD
    Renda, T.
    Baraldo, S.
    Pelaia, G.
    Bazzan, E.
    Turato, G.
    Papi, A.
    Maestrelli, P.
    Maselli, R.
    Vatrella, A.
    Fabbri, L. M.
    Zuin, R.
    Marsico, S. A.
    Saetta, M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) : 62 - 69
  • [46] Azastilbenes: a cut-off to p38 MAPK inhibitors
    Poon, Jia-Fei
    Alao, John Patrick
    Sunnerhagen, Per
    Diner, Peter
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11 (27) : 4526 - 4536
  • [47] The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
    Yong, Hae-Young
    Koh, Min-Soo
    Moon, Aree
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (12) : 1893 - 1905
  • [48] Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules
    Casadome-Perales, Alvaro
    De Matteis, Laura
    Alleva, Maria
    Infantes-Rodriguez, Cristina
    Palomares-Perez, Irene
    Saito, Takashi
    Saido, Takaomi C.
    Esteban, Jose A.
    Nebreda, Angel R.
    de la Fuente, Jesus M.
    Dotti, Carlos G.
    [J]. NANOMEDICINE, 2019, 14 (18) : 2409 - 2422
  • [49] The as-yet unfulfilled promise of p38 MAPK inhibitors
    Susan E. Sweeney
    [J]. Nature Reviews Rheumatology, 2009, 5 : 475 - 477
  • [50] P38α MAPK is required for contact inhibition
    Faust, D
    Dolado, I
    Cuadrado, A
    Oesch, F
    Weiss, C
    Nebreda, AR
    Dietrich, C
    [J]. ONCOGENE, 2005, 24 (53) : 7941 - 7945